NCT04001725 2019-11-13OPTIMALFondazione IRCCS Istituto Nazionale dei Tumori, MilanoPhase 2 Unknown110 enrolled
NCT02445872 2015-12-09Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin ChemotherapyZhejiang UniversityPhase 2 Unknown80 enrolled